# A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

> clinical trial · VERIFIED · 2026-07-08

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Breast Neoplasms

- Company: Novartis Pharmaceuticals
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06830720

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.